New York, May 12, 2026, 17:11 EDT
- Oscar Health was quoted at $23.73 late Tuesday, up about $1.73, after touching $23.76 intraday; volume was near 13 million shares.
- The move rests on a simple read: investors are giving more weight to profit quality than to the Q1 revenue miss.
- Bulls see pricing power, lower claims intensity and scale. Bears still point to ACA enrollment churn and policy risk after enhanced subsidies expired.
Oscar Health’s stock pushed higher again Tuesday, extending a post-earnings run that has turned the chart from a recovery trade into a sharper bet on execution. The shares were quoted at $23.73 late in the day, up roughly 7.9%, after opening at $21.73 and trading as high as $23.76.
The “why” is not hard to find. Oscar missed revenue expectations in Q1, but the market looked past that because profit, claims costs and operating leverage were much better than feared. Revenue rose 52.6% year over year to $4.65 billion, while GAAP EPS of $2.07 beat consensus and adjusted EBITDA came in far above estimates. Barchart.com
This is a margin story first. Oscar’s medical loss ratio, the share of premiums spent on medical claims, fell to 70.5% from 75.4% a year earlier. The company said the improvement came from pricing discipline, claims and risk-adjustment seasonality, and $68 million of favorable prior-period development. Risk adjustment is the ACA system that moves money between insurers based on how sick their members are.
Management sounded more controlled than promotional on the call. CEO Mark Bertolini said the individual market is “resilient,” while CFO Richard Blackley said payment rates were consistent year over year and “modestly favorable” to plan despite the sunset of enhanced premium tax credits. That matters because Oscar is heavily tied to individual ACA exchange plans, where affordability can drive whether members actually keep coverage. The Motley Fool
The stock also had help from the tape. Managed-care names were bid broadly: Centene rose about 5.2%, UnitedHealth gained about 3.1%, and Elevance Health added about 3.1%. Oscar still outpaced them, which suggests buyers were not only buying health insurers; they were buying a company-specific earnings reset.
The bull case is cleaner now. Oscar has 3.17 million members, up from 2.04 million a year earlier, and Q1 net income attributable to the company rose to about $679 million from $275 million. Bertolini said Oscar remains on track to “significantly expand margins” and reach “meaningful profitability” in 2026. SEC
The bear case starts in the same place: ACA exposure. CMS said 23.1 million consumers selected or were automatically re-enrolled in 2026 marketplace coverage, but the market has shifted toward cheaper Bronze plans and away from Silver plans. That can help affordability at the front end, but it may also signal pressure on household budgets and plan mix.
There is a more immediate worry, too. Axios reported Tuesday that ACA coverage is down by about 1.2 million people versus last year after Congress did not extend enhanced subsidies, and cited Wakely’s estimate that 2026 enrollment could end the year 17% to 26% below last year. Larry Levitt of KFF called it a “substantial drop in enrollment.” Axios
Prediction markets point to the same policy overhang, not a fresh rescue. Polymarket’s ACA page showed its most active ACA market assigning an 87% chance to “Not Extended & Democratic Party,” a combined outcome tied to the subsidy issue and 2026 House control. For Oscar, that is not a direct earnings input today, but it shows traders treating the subsidy lapse as the base case rather than a short-term upside surprise. Polymarket
So Tuesday’s rally is rational, but not risk-free. Investors are rewarding Oscar for proving it can price plans, hold down claims and spread fixed costs over a larger base. They are also assuming Q1 was not just seasonal sweetness.
That is the next test. If claims rise later in the year, if risk adjustment swings the wrong way, or if healthier members leave ACA plans faster than expected, today’s multiple gets harder to defend. For now, the market is saying Oscar’s earnings power looks more real than it did a week ago.
